RGEN Repligen
- 172.480
- +9.140+5.60%
- 170.270
- -2.210-1.28%
Repligen News
Here's Why It's Unlikely That Repligen Corporation's (NASDAQ:RGEN) CEO Will See A Pay Rise This Year
Key Insights Repligen's Annual General Meeting to take place on 16th of May Salary of US$880.0k is part of CEO Tony Hunt's total remuneration Total compensation is 35% above industry average Rep
There May Be Some Bright Spots In Repligen's (NASDAQ:RGEN) Earnings
The market for Repligen Corporation's (NASDAQ:RGEN) shares didn't move much after it posted weak earnings recently. Our analysis suggests that while the profits are soft, the foundations of the busin
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the
Repligen First Quarter 2024 Earnings: EPS Misses Expectations
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Express News | Repligen Corp : Stephens Cuts Target Price to $200 From $215
Repligen Is Maintained at Overweight by JP Morgan
Repligen Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200
Repligen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 24.63% JP Morgan $230 → $200 Maintains Overweight 02/22/2024 28.99% Stifel $165 → $207 Maintain
Express News | Repligen Corp : UBS Cuts Target Price to $205 From $225
Express News | Repligen Corp : Jefferies Cuts Target Price to $170 From $180
Earnings Call Summary | Repligen(RGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Repligen Corporation (RGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Q1 2024 revenue was $151 million and Repligen is on track to achieve between $300 m
Repligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment With Analyst Projections
Repligen's Q1 Adjusted Earnings, Revenue Fall
Repligen (RGEN) reported Q1 adjusted earnings Wednesday of $0.28 per diluted share, down from $0.64 a year earlier. Analysts polled by Capital IQ expected $0.30. Revenue for the quarter ended March 31
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Adjusted Q1 EPS $0.28, Vs. Street Est of $0.30
07:36 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Adjusted Q1 EPS $0.28, vs. Street Est of $0.30
Express News | Repligen Reaffirms 2024 Adjusted EPS Guidance Of $1.42-$1.49 Versus Consensus Of $1.46
Express News | Repligen Reaffirms 2024 Sales Guidance Of $620M-$650M Versus Consensus Of $637.79M
Express News | Repligen Corp: Continuing to Expect That Orders Will Pick up During Second Half of Year
Express News | Repligen Corp: Reiterated Its Financial Guidance for Full Year 2024
Express News | Repligen Q1 Adjusted Operating Income USD 11.8 Million Vs. Ibes Estimate USD 16.6 Million
Analysis
Price Target
No Data
